One of the main challenges associated with late-onset genetic neurodegenerative diseases is predicting when the condition begins and how it progresses over time. In a new study, Tabrizi et al. have used a range of imaging, clinical and neuropsychiatric measures to assess the progression of Huntington disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
[No authors listed] A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72, 971–983 (1993).
Bates, G. P., Harper, P. S. & Jones, A. L. (eds) Huntington's Disease, Oxford Monographs on Medical Genetics. 3rd edn Vol. 1 (Oxford University Press, Oxford, 2002).
Morton, A. J. et al. Disintegration of the sleep–wake cycle and circadian timing in Huntington's disease. J. Neurosci. 25, 157–163 (2005).
Goodman, A. O. et al. The metabolic profile of early Huntington's disease—a combined human and transgenic mouse study. Exp. Neurol. 210, 691–698 (2008).
Kirkwood, S. C. et al. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch. Neurol. 57, 1040–1044 (2000).
Paulsen, J. S. et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 79, 874–880 (2008).
Bechtel, N. et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 75, 2150–2160 (2010).
Tabrizi, S. J. et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 10, 31–42 (2011).
Ross, C. A. & Shoulson, I. Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Relat. Disord. 15 (Suppl. 3), S135–S138 (2009).
Squitieri, F. et al. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 126, 946–955 (2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Barker, R., Mason, S. Tracking disease progress in Huntington disease. Nat Rev Neurol 7, 192–193 (2011). https://doi.org/10.1038/nrneurol.2011.37
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.37
